Add-on nemolizumab beneficial in steroid-refractory atopic dermatitis

  • Silverberg JI & al.
  • J Allergy Clin Immunol
  • 23.08.2019

  • von Brian Richardson, PhD
  • Clinical Essentials
Der Zugang zum gesamten Inhalt dieser Seite ist nur Angehörigen medizinischer Fachkreise vorbehalten. Der Zugang zum gesamten Inhalt dieser Seite ist nur Angehörigen medizinischer Fachkreise vorbehalten.

Takeaway

  • Add-on nemolizumab is associated with clinical benefit in patients with moderate to severe atopic dermatitis (AD) inadequately controlled with topical corticosteroids (TCS), according to data from a phase 2b randomized controlled trial.

Why this matters

  • Nemolizumab offers a novel mechanism for AD treatment and has already shown efficacy as monotherapy.

Study design

  • 226 patients with TCS-refractory moderate to severe AD and severe pruritus were assigned to receive nemolizumab (10, 30, or 90 mg; n=169) or placebo (n=57) in addition to TCS.
  • Funding: Nestlé Skin Health–Galderma R&D.

Key results

  • Nemolizumab 30 mg was associated with improved Eczema Area and Severity Index (EASI) compared with placebo at week 16 (P<.01 and week>
  • Nemolizumab 30 mg was associated with improved rates of >50% improvement in EASI (EASI-50) compared with placebo at week 16 (P=.016) and week 24 (P=.014).
  • Nemolizumab 30 mg was associated with improvements in peak pruritus numeric rating scale compared with placebo at week 16 (P≤.001) and week 24 (P≤.001).
  • Serious treatment-emergent adverse events were reported in 5.5% of patients receiving nemolizumab 10 mg, 3.5% of patients receiving nemolizumab 30 or 90 mg, and 1.8% of patients receiving placebo.

    Limitations

    • Relatively short follow-up.
    • Small sample size.